Our customers' Feedback
Search:
Perform search
Categories list

Generic Onglyza

News
Onglyza
Onglyza photo

Generic Onglyza (Saxagliptin)

Diabetes

PackagePricePer PillSavingsOrder
5mg × 28 pills$124.95$4.46Add to cart
5mg × 56 pills$224.95$4.02$24.95Add to cart
5mg × 84 pills$309.95$3.69$64.90Add to cart

Most popular quantity.
Prandin
$ 0.83
Generic Prandin
(Repaglinide 0.5/1/2mg)
Precose
$ 0.96
Generic Precose
(Acarbose 25/50mg)
Starlix
$ 0.83
Generic Starlix
(Nateglinide 60/120mg)
Actoplus Met
$ 1.30
Generic Actoplus Met
(Metformin And Pioglitazone 500mg)
Actos
$ 1.22
Generic Actos
(Pioglitazone Hydrochloride 15/30mg)
Amaryl
$ 1.00
Generic Amaryl
(Glimepiride 1/2/4mg)
Social bookmarks:
Choose your language:



Money backguarantee
Secureshopping

Our billing is certified by:

Secure shopping certificates

Special Offer!

  • FDA Requires New Heart Failure Warnings on Onglyza Label - Legal Examiner

    FDA Requires New Heart Failure Warnings on Onglyza LabelLegal ExaminerThe FDA has recently announced that new warnings will be added to the labels of both Onglyza (saxagliptin) and Nesina (alogliptin), cautioning that they may increase the risk for heart failure, especially in patients who already have kidney disease or .

  • Merck's 2Q16 Estimates: Expect Operational Growth in Revenues - Market Realist

    Merck's 2Q16 Estimates: Expect Operational Growth in RevenuesMarket RealistThe competitors for Januvia and its combination version Janumet are Onglyza, jointly made by Bristol-Myers Squibb (BMY) and AstraZeneca (AZN), and Galvus from Novartis (NVS).

  • Which Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings? - Market Realist

    Market RealistWhich Growth Platforms Will Drive AstraZeneca's 2Q16 Earnings?Market RealistThe diabetes franchise includes drugs like Onglyza, Bydureon, Byetta, and Farxiga.

  • Why Analysts Think AstraZeneca's Revenues Will Fall in 2Q16 - Market Realist

    Why Analysts Think AstraZeneca's Revenues Will Fall in 2Q16Market RealistAnalysts expect strong performances from Brilinta, Onglyza, Bydureon, and Farxiga to drive the growth of this segment for 2Q16 while there might be a decline in revenues of Byetta and legacy drugs Crestor and Atacand.

  • FDA warns on heart failure risk associated with Onglyza, Nesina - BioPharma Dive

    FDA warns on heart failure risk associated with Onglyza, NesinaBioPharma DiveThe FDA is adding new warnings to the labels for AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin) after an internal safety review found an increased risk of heart failure with the two diabetes drugs.

    Copyright © cheapgenerics24.com